Selexipag is a selective prostacyclin receptor agonist that was administered to 84 SLE patients with PAH, at doses of 200–1600 μg twice daily and seemed to delay the progression of the disease according to this randomized control trial [61]. This evidence concerns the gene PTGIR and systemic lupus erythematosus.